245 related articles for article (PubMed ID: 22341844)
1. Complications of PORT-A-CATH® in patients with sickle cell disease.
Alkindi S; Matwani S; Al-Maawali A; Al-Maskari B; Pathare A
J Infect Public Health; 2012 Mar; 5(1):57-62. PubMed ID: 22341844
[TBL] [Abstract][Full Text] [Related]
2. Experience with the Port-A-Cath in sickle cell disease.
McCready CE; Doughty HA; Pearson TC
Clin Lab Haematol; 1996 Jun; 18(2):79-82. PubMed ID: 8866138
[TBL] [Abstract][Full Text] [Related]
3. Complications and Management of Totally Implantable Central Venous Access Ports in Cancer Patients at a University Hospital in Oman.
D'Souza PC; Kumar S; Kakaria A; Al-Sukaiti R; Al-Baimani K; Hamid RS; Mittal AK; Al-Balushi M; Burney IA; Al-Moundhri MS
Sultan Qaboos Univ Med J; 2021 Feb; 21(1):e103-e109. PubMed ID: 33777430
[TBL] [Abstract][Full Text] [Related]
4. Use of a dual lumen port for automated red cell exchange in adults with sickle cell disease.
Shrestha A; Jawa Z; Koch KL; Rankin AB; Xiang Q; Padmanabhan A; Karafin MS; Field JJ
J Clin Apher; 2015 Dec; 30(6):353-8. PubMed ID: 25790325
[TBL] [Abstract][Full Text] [Related]
5. Use of infusion ports in patients with sickle cell disease: Indications and complications.
Ilonze C; Anderson M; Stubblefield A; Journeycake J; Sinha AA
Pediatr Blood Cancer; 2022 Feb; 69(2):e29445. PubMed ID: 34786823
[TBL] [Abstract][Full Text] [Related]
6. Use of port-a-cath in cancer patients: a single-center experience.
D'Souza PC; Kumar S; Kakaria A; Al-Sukaiti R; Zahid KF; Furrukh M; Burney IA; Al-Moundhri MS
J Infect Dev Ctries; 2014 Nov; 8(11):1476-82. PubMed ID: 25390061
[TBL] [Abstract][Full Text] [Related]
7. Portacaths are safe for long-term regular blood transfusion in children with sickle cell anaemia.
Bartram JL; O'Driscoll S; Kulasekararaj AG; Height SE; Dick M; Patel S; Rees DC
Arch Dis Child; 2011 Nov; 96(11):1082-4. PubMed ID: 20605863
[TBL] [Abstract][Full Text] [Related]
8. Central venous port implantations via the cephalic vein applying an intravasal electrographic control of the catheter tip position: a single-center experience of 316 cases.
Schenck M; Schneider T; Rübben H; Eisenhardt A
World J Urol; 2012 Jun; 30(3):399-404. PubMed ID: 21874511
[TBL] [Abstract][Full Text] [Related]
9. Complications of implantable venous access devices in patients with sickle cell disease.
Shah N; Landi D; Shah R; Rothman J; De Castro LM; Thornburg CD
Am J Hematol; 2012 Feb; 87(2):224-6. PubMed ID: 22081438
[TBL] [Abstract][Full Text] [Related]
10. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.
Biffi R; de Braud F; Orsi F; Pozzi S; Mauri S; Goldhirsch A; Nolè F; Andreoni B
Ann Oncol; 1998 Jul; 9(7):767-73. PubMed ID: 9739444
[TBL] [Abstract][Full Text] [Related]
11. Port-A-Cath insertions in acute leukaemia and childhood malignancies.
Loh AH; Chui CH
Asian J Surg; 2007 Jul; 30(3):193-9. PubMed ID: 17638639
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of device-associated infections related to a long-term implantable vascular access device.
Sotir MJ; Lewis C; Bisher EW; Ray SM; Soucie JM; Blumberg HM
Infect Control Hosp Epidemiol; 1999 Mar; 20(3):187-91. PubMed ID: 10100545
[TBL] [Abstract][Full Text] [Related]
13. Cathlink 20: a subcutaneous implanted central venous access device used in children with sickle cell disease on long-term erythrocytapheresis--a report of low complication rates.
Raj A; Bertolone S; Bond S; Burnett D; Denker A
Pediatr Blood Cancer; 2005 Jun; 44(7):669-72. PubMed ID: 15700248
[TBL] [Abstract][Full Text] [Related]
14. Totally implantable central venous catheters of the port-a-cath type: complications due to its use in the treatment of cancer patients.
Granic M; Zdravkovic D; Krstajic S; Kostic S; Simic A; Sarac M; Ivanovic N; Radovanovic D; Dikic S; Kovcin V
J BUON; 2014; 19(3):842-6. PubMed ID: 25261677
[TBL] [Abstract][Full Text] [Related]
15. Polyurethane versus silicone catheters for central venous port devices implanted at the forearm.
Wildgruber M; Lueg C; Borgmeyer S; Karimov I; Braun U; Kiechle M; Meier R; Koehler M; Ettl J; Berger H
Eur J Cancer; 2016 May; 59():113-124. PubMed ID: 27023050
[TBL] [Abstract][Full Text] [Related]
16. Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications.
Abdul-Rauf A; Gauderer M; Chiarucci K; Berman B
J Pediatr Hematol Oncol; 1995 Nov; 17(4):342-5. PubMed ID: 7583391
[TBL] [Abstract][Full Text] [Related]
17. Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer.
Beckers MM; Ruven HJ; Seldenrijk CA; Prins MH; Biesma DH
Thromb Res; 2010 Apr; 125(4):318-21. PubMed ID: 19640573
[TBL] [Abstract][Full Text] [Related]
18. [Totally implantable venous access systems. Analysis of complications].
D'Angelo F; Ramacciato G; Caramitti A; Aurello P; Lauro S; Bordin F; Della Casa U
Minerva Chir; 1997; 52(7-8):937-42. PubMed ID: 9411296
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of radiologically implanted central venous port systems explanted due to complications.
Teichgräber UK; Kausche S; Nagel SN
J Vasc Access; 2011; 12(4):306-12. PubMed ID: 21534232
[TBL] [Abstract][Full Text] [Related]
20. Radiologic placement of a low profile implantable venous access port in a pediatric population.
Nosher JL; Bodner LJ; Ettinger LJ; Siegel RL; Gribbin C; Asch J; Drachtman RA
Cardiovasc Intervent Radiol; 2001; 24(6):395-9. PubMed ID: 11907746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
